Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XPH vs XHE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XHE Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

XHE Overall Winner 6-Pillar Tally: XPH 0 – 0 XHE (6 Tie) Matrix Metrics: XPH 1 – 2 XHE

As of Nov 16, 2026, SPDR S&P Health Care Equipment ETF (XHE) is the stronger overall head-to-head candidate over SPDR S&P Pharmaceuticals ETF (XPH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XPH carries a Unified Composite Score of 41.0/100 (SELL) at $65.58 (N/M Forward P/E, N/A operating margin), whereas XHE carries 46.8/100 (HOLD) at $93.83 (N/M Forward P/E, N/A operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XPH vs XHE
XPH NYSE Arca
SPDR S&P Pharmaceuticals ETF
Institutional Equity
$65.58
-1.87% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.87β · 32% Vol
Unified Composite Score
41.0 / 100 SELL
Tech 37.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $65.05 · SMA50: $65.32
XHE NYSE Arca Head-to-Head Winner
SPDR S&P Health Care Equipment ETF
Institutional Equity
$93.83
-1.1% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.87β · 39% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.1 · SMA20: $94.20 · SMA50: $91.98

6-Pillar Scorecard Institutional Category Breakdown (XPH 0 – 0 XHE)

Columns: Metric · XPH · XHE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 20.9% (5th %ile) 252.7% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XPH (1) vs XHE (2)
Institutional Metric XPH XHE Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
64% ($50–$74) 72% ($76–$101) Stronger Trend XHE
Beta / 30D Volatility
Risk Regime
0.87β · 32% Vol 0.87β · 39% Vol Lower Realized Risk XPH
Unified Institutional Score
Composite Signal
41.0 / 100 (SELL) 46.8 / 100 (HOLD) Higher Composite XHE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XPH +1.15 pp
XPH: +6.05% · XHE: +4.9%
3M Horizon XHE +8.33 pp
XPH: -9.48% · XHE: -1.15%
6M Horizon XHE +1.52 pp
XPH: +17.59% · XHE: +19.11%
1Y Horizon XPH +17.34 pp
XPH: +30.61% · XHE: +13.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XPH vs XHE. Trailing 12-month operating profitability (XPH N/A vs XHE N/A) and valuation multiples (XPH N/M vs XHE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

XPH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
XHE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.9%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XHE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 252.7%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XHE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XPH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
XHE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ XPH vs XHE Key Questions & Quantitative Answers

As of Nov 16, 2026, SPDR S&P Health Care Equipment ETF (XHE) is the stronger overall head-to-head candidate over SPDR S&P Pharmaceuticals ETF (XPH) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XPH carries a Unified Composite Score of 41.0/100 (SELL) at $65.58 (N/M Forward P/E, N/A operating margin), whereas XHE carries 46.8/100 (HOLD) at $93.83 (N/M Forward P/E, N/A operating margin). Technically, XPH sits in a Neutral phase (RSI 51.5, UNCLASSIFIED options structure) and XHE sits in a Neutral phase (RSI 51.1, UNCLASSIFIED options structure).

XPH and XHE split Growth & Scale metrics: XPH posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XHE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XPH generates N/A in USD-normalized revenue versus N/A for XHE. In operating R&D and SG&A reinvestment, XPH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XHE.

XPH and XHE trade at balanced relative valuation multiples. XPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XHE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XPH (N/A ROE) versus XHE (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, XPH carries 20.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 32% Vol realized risk). By comparison, XHE carries 252.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 39% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.